RA Capital Healthcare Fund LP 4

What Happened
RA Capital Management, L.P. (a reported 10% owner via its RA Capital Healthcare Fund) acquired a total of 223,596 Adicet Bio (ACET) shares in three open-market purchases in February 2026. The buys were: 74,577 shares at a weighted-average $7.04 ($525,022) on 2026-02-18; 74,268 shares at $7.21 ($535,472) on 2026-02-19; and 74,751 shares at $7.27 (~$543,440) on 2026-02-20 — about $1.60 million total. These were purchases (buying = generally a more informative/bullish signal than sales), not sales or option exercises.

Key Details

• Transaction dates and reported weighted-average prices:
  • 2026-02-18: 74,577 shares @ $7.04 (~$525,022)
  • 2026-02-19: 74,268 shares @ $7.21 (~$535,472)
  • 2026-02-20: 74,751 shares @ $7.27 (~$543,440)
• Total shares bought: 223,596; total reported value: ~$1,603,934.
• Shares held after transaction: not specified in the provided excerpt.
• Footnotes of note:
  • Reported prices are weighted averages from multiple trades; component prices reported in the filing range roughly $6.89 to $7.58.
  • RA Capital Management is the adviser to RA Capital Healthcare Fund; the Fund directly holds the shares and the adviser/disclosers disclaim beneficial ownership except for pecuniary interest.
• Filing timeliness: The Form 4 was filed 2026-04-13 for February trades (transactionTimeliness = 'L'), indicating a late filing. Late filings reduce timely public transparency and can carry regulatory attention.

Context

• This activity is institutional (a 10% owner via a fund), not an individual executive or director trade; institutional purchases are commonly portfolio/investment decisions rather than personal insider signals.
• No options, awards, gifts, or tax-withholding events are reported here — only open-market purchases.